CCL24 as a diagnostic and therapeutic target for breast cancer
Inventors
Assignees
Publication Number
US-11988672-B2
Publication Date
2024-05-21
Expiration Date
2040-11-24
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Using expression of CC chemokine ligand (CCL24) to serve as an identification of a potential deriver of metastatic cancers and methods of detecting the presence of CCL24 to serve as a breast cancer diagnosis tool.
Core Innovation
The invention describes the use of CC chemokine ligand (CCL24) as a diagnostic and therapeutic target for breast cancer. It provides methods to detect and measure CCL24 expression in breast tumor microenvironments, especially in aggressive subtypes like triple negative breast cancer, using immune-based staining techniques. The expression level of CCL24 in breast tumor cells is used to distinguish between non-triple negative and triple negative breast cancer cells.
The patent addresses the critical need for more effective biomarkers and therapeutic targets for metastatic breast cancer. Current therapies do not significantly alter mortality due to disease recurrence and metastasis, particularly in aggressive forms like triple negative breast cancer. By identifying CCL24 as a potential driver of metastatic behavior, the invention seeks to provide new means for early diagnosis and targeted intervention.
The approach includes analyzing breast cancer samples for CCL24 through immunohistochemistry and multiplexed immunofluorescence, measuring the presence and activity of immune suppressor cells, and investigating the polarization of tumor-associated macrophages. Therapeutically, the patent further discloses that inhibiting or knocking down CCL24 may suppress cancer cell metastasis and modulate the tumor immune microenvironment, with the expectation of reducing the progression and mortality associated with metastatic breast cancer.
Claims Coverage
There are two primary inventive features covered by the independent claims in this patent.
Immunohistochemistry method for CCL24 detection in breast cancer
This inventive feature involves: - Obtaining at least one breast cell tissue sample from a subject to detect the presence of a tumor microenvironment. - Employing immunohistochemistry staining of the breast cell tissue sample to identify cancer cell compartments. - Measuring for differential expression of CC Chemokine Ligand 24 (CCL24) in the tumor microenvironment to differentiate between non-Triple Negative tumorigenic cells and Triple Negative Breast Cancer cells. - Measuring lymphocyte tracking events in the tumor microenvironment by gating at least one lymphocyte using anti-CD45 antibody to analyze T-regulatory cells and myeloid-derived suppressor cells. - Measuring the amount of CCL24 in the tumor microenvironment via multiplexed immunofluorescence to determine if the subject is positive for at least one Triple Negative Breast Cancer cell.
Immunohistochemistry method for serum-based CCL24 as breast cancer biomarker
This inventive feature comprises: - Examining a subject by obtaining at least one breast cell tissue sample to detect the presence of a tumor microenvironment. - Employing immunohistochemistry staining to identify at least one cancer cell compartment in the tissue sample. - Measuring for a differential expression of serum-based biomarker CCL24 in the tumor microenvironment to differentiate between non-Triple Negative tumorigenic cells and Triple Negative Breast Cancer cells. - Measuring the amount of CCL24 in the tumor microenvironment via multiplexed immunofluorescence to determine if the subject is positive for at least one Triple Negative Breast Cancer cell.
The inventive features cover methods employing immunohistochemistry and multiplexed immunofluorescence to measure CCL24 in breast tissue samples for differentiating aggressive breast cancer subtypes, as well as measuring immune-related parameters within the tumor microenvironment.
Stated Advantages
Allows early diagnosis of aggressive breast cancer, particularly triple negative breast cancer, through detection of CCL24 expression.
Provides a potential therapeutic target by enabling inhibition or knockdown of CCL24 to reduce migration and metastasis of breast cancer cells.
Facilitates characterization of immune suppressive events in the tumor microenvironment, which may inform improved treatment strategies.
Offers a novel biomarker for predicting poor prognosis and guiding personalized treatment decisions in breast cancer patients.
Documented Applications
Use of CCL24 detection as a diagnostic tool for identifying triple negative or aggressive breast cancer cells in patient tissue samples.
Application of CCL24 measurement to differentiate non-triple negative tumorigenic cells from triple negative breast cancer cells.
Utilization of CCL24 as a therapeutic target, where its inhibition may reduce immune suppressor cell activity and suppress breast cancer migration and metastasis.
Interested in licensing this patent?